Short-course aminoglycosides as adjunctive treatment in adults with sepsis (SAGA) - a cluster-randomized trial

This record includes meta-data from the SAGA trial, a cluster-randomized trial that was performed in the Netherlands between 2022 and 2023.
Nine acute care hospitals were randomized to preferred empirical treatment of patients hospitalized with sepsis with either ceftriaxone or cefuroxime monotherapy (monotherapy arm; four hospitals) or cefuroxim combined with an aminoglycoside (combination arm; five hospitals). The primary outcome was 30-day all-cause mortality. The aim was to cross-over to the alternative intervention after one year. However, the trial was prematurely terminated to due non-compliance with the combination arm and low recruitment rates.